阿托伐他汀对急性冠脉综合征患者血浆纤维蛋白原和C反应蛋白的影响

目的：观察阿托伐他汀治疗对于急性冠脉综合征患者血浆纤维蛋白原和c反应蛋白的影响。方法：本试验采用前瞻性开放性病例对照研究，将84例急性冠脉综合征患者随机分为2组：A组（41例）采用常规治疗；B组（43例）在常规药物治疗基础上，加用阿托伐他汀（20mg／d）治疗，在治疗前以及治疗2个月后检测患者血浆纤维蛋白原及超敏C反应蛋白水平。结果：常规治疗对血浆纤维蛋白原和超敏c反应蛋白水平无明显影响；阿托伐他汀不但能降低血浆纤维蛋白原水平，还显著降低c反应蛋白水平。结论：阿托伐他汀改善急性冠脉综合征患者血液流变学，并具有抗炎作用，对于抑制心肌缺血的进展具有良好作用。

Effects of atorvastatin on plasma fibrinogen and C-reactive protein levels in patients with acute coronary syndrome

Objective:To investigate the effects of atorvastatin on plasma fibrinogen and C-reactive protein(CRP) levels in patients with acute coronary syndrome.Methods:Eighty-four patients with acute coronary syndrome were enrolled in our study,and divided into 2 groups at random:Group A(41 subjects) were treated with conventional therapy,and Group B(43 subjects) were treated with atorvastatin(20mg/d)combined with conventional therapy.They all received the treatment for 2 months.Plasma CRP and fibrinogen levels were determined at baseline and after treatment.Results: Conventional therapy had no obvious effects on fibrinogen or CRP levels,administration of atorvastatin combined with conventional therapy could not only lower fibrinogen,but also significantly decreased CRP levels.Conclusions: Atorvastatin could improve the hemorheology of patients with acute coronary syndrome and inhibit inflammation,which may contribute to the prevention of advancement of myocardial ischemia.